Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

Published 2017 View Full Article

Authors

Keywords

Journal

HAEMATOLOGICA

Volume 103, Issue 1, Pages 107-115

Publisher

Ferrata Storti Foundation (Haematologica)

Online

2017-10-28

DOI

10.3324/haematol.2017.176917

Ask authors/readers for more resources

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

HAEMATOLOGICA

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Find the ideal target journal for your manuscript

Ask a Question. Answer a Question.